La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Eiger BioPharmaceuticals Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Eiger BioPharmaceuticals.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.5%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 01

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Jan 04

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Dec 20

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Nov 09

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Oct 06

Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon

Apr 06

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Eiger BioPharmaceuticals non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:EIGR.Q - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2023	16	-75	-75	-75	N/A
9/30/2023	15	-87	-83	-83	N/A
6/30/2023	15	-96	-89	-89	N/A
3/31/2023	15	-97	-89	-89	N/A
12/31/2022	13	-97	-83	-83	N/A
9/30/2022	14	-93	-78	-78	N/A
6/30/2022	13	-89	-76	-76	N/A
3/31/2022	11	-86	-75	-75	N/A
12/31/2021	12	-34	-71	-71	N/A
9/30/2021	9	-31	-70	-70	N/A
6/30/2021	6	-24	-65	-65	N/A
3/31/2021	4	-21	-60	-60	N/A
12/31/2020	N/A	-65	-63	-63	N/A
9/30/2020	N/A	-63	-63	-63	N/A
6/30/2020	N/A	-66	-64	-63	N/A
3/31/2020	N/A	-68	-63	-62	N/A
12/31/2019	N/A	-70	-64	-64	N/A
9/30/2019	N/A	-70	-61	-61	N/A
6/30/2019	N/A	-68	-60	-60	N/A
3/31/2019	N/A	-61	-53	-53	N/A
12/31/2018	N/A	-52	-43	-43	N/A
9/30/2018	N/A	-47	-41	-41	N/A
6/30/2018	N/A	-39	-35	-35	N/A
3/31/2018	N/A	-40	-36	-36	N/A
12/31/2017	N/A	-42	-38	-38	N/A
9/30/2017	N/A	-44	N/A	-39	N/A
6/30/2017	N/A	-47	N/A	-38	N/A
3/31/2017	N/A	-49	N/A	-45	N/A
12/31/2016	N/A	-47	N/A	-38	N/A
9/30/2016	N/A	-41	N/A	-30	N/A
6/30/2016	N/A	-33	N/A	-25	N/A
3/31/2016	N/A	-22	N/A	-12	N/A
12/31/2015	N/A	-13	N/A	-9	N/A
9/30/2015	N/A	-7	N/A	-6	N/A
12/31/2014	N/A	-2	N/A	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista EIGR.Q è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di EIGR.Q cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di EIGR.Q cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di EIGR.Q cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di EIGR.Q cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di EIGR.Q è previsto essere elevato tra 3 anni

Eiger BioPharmaceuticals Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 67% to US$30.00

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$1.45 loss

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$1.57 loss, revenue downgraded

Consensus EPS estimates upgraded to US$1.07 loss, revenue downgraded

Recent updates

Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.

Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.

Spruce Biosciences, Inc. (NasdaqGS:SPRB) completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.

Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.

Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index

The Nasdaq Stock Market LLC Determines Eiger Biopharmaceuticals' Common Stock to be Delisted from Nasdaq

Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy

Price target decreased by 67% to US$30.00

Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024

Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals

Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals

Eiger BioPharmaceuticals Receives Deficiency Letter from Nasdaq Regarding No Longer Satisfies the $10 Million Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Global Market

New major risk - Negative shareholders equity

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Market cap size

Eiger BioPharmaceuticals, Inc. Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

No longer forecast to breakeven

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eiger BioPharmaceuticals Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1)

New major risk - Share price stability

Consensus EPS estimates upgraded to US$1.45 loss

Eiger Biopharmaceuticals, Inc. Appoints David Apelian, as CEO

Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from Russell Small Cap Comp Value Index

No longer forecast to breakeven

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to US$1.57 loss, revenue downgraded

Consensus EPS estimates upgraded to US$1.07 loss, revenue downgraded

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues miss analyst expectations

Eiger BioPharmaceuticals, Inc. Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

Independent Chairman recently bought US$72k worth of stock

Eiger BioPharmaceuticals, Inc. Announces Sriram Ryali to Resign as Chief Financial Officer, Effective January 20, 2023

Forecast to breakeven in 2025

Key Executive recently bought US$128k worth of stock

RM LAW Announces Class Action Lawsuit Against Eiger Biopharmaceuticals, Inc

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Eiger BioPharmaceuticals, Inc. Announces CEO Changes

Price target decreased to US$9.25

Eiger BioPharmaceuticals, Inc. Announces Topline Primary Week 48 Data from Its Landmark Phase 3 D-LIVR study

Forecast to breakeven in 2024

Pomerantz Law Firm Announces the Filing of a Class Action Against Eiger BioPharmaceuticals, Inc

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Third quarter 2022 earnings: EPS misses analyst expectations

Eiger BioPharmaceuticals, Inc. Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Eiger Biopharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

Eiger Biopharmaceuticals Inc. Announces European Commission (Ec) Has Granted Marketing Authorization for Zokinvy® (Lonafarnib

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Eiger BioPharmaceuticals, Inc. Appoints Lisa Kelly-Croswell to Board of Directors

Eiger BioPharmaceuticals, Inc. Announces Results from Multiple Presentations at the European Association for the Study of the Liver International Liver Congress 2022

Eiger Biopharmaceuticals, Inc. Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries

Insufficient new directors

Eiger Biopharmaceuticals, Inc. Receives Positive Chmp Opinion for Zokinvy as A Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

Consensus revenue estimates fall by 22%

Insufficient new directors

Price target increased to US$32.00

Eiger BioPharmaceuticals, Inc. Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program

Eiger Biopharmaceuticals, Inc. Announces New Executive Appointments

Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon